Immunolocalization of protectin (CD59) and macrophages in polymyositis and dermatomyositis

Journal of Neuroimmunology

Volumn 149, Issue 1-2, 2004, Pages 187-194

  Gendek Kubiak, Hanna ^a   Gendek, Ewa G ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

CD59; Complement; Dermatomyositis; Macrophages; Polymyositis

Indexed keywords

ANTIGEN; CD59 ANTIGEN; COMPLEMENT;

ADULT; ARTICLE; CELL DEGENERATION; CELL PROTECTION; CELL SURFACE; CELL VACUOLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DERMATOMYOSITIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MACROPHAGE; MONOCYTE; MUSCLE; MUSCLE CELL; MUSCLE INJURY; PATIENT; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REACTION ANALYSIS; VASCULAR ENDOTHELIUM;

ANTIGENS, CD59; BLOOD VESSELS; DERMATOMYOSITIS; ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MUSCLE, SKELETAL; NEURAL CELL ADHESION MOLECULES; POLYMYOSITIS; STAINING AND LABELING;

EID: 1542500681     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2003.12.023     Document Type: Article

References (34)

1. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies: I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 16:1984;193-208.
2. Basta M., Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94:1994;1729-1735.
3. Bohan, A., Peter, J.B., 1975. Polymyositis and dermatomyositis. N. Engl. J. Med. 292, 344-347, 403-407.
4. Cashman N.R., Covault J., Wollman R.L., Sanes J.R. Neural cell adhesion molecule in normal, denervated, and myopathic human muscle. Ann. Neurol. 21:1987;481-489.
5. Cherin P., Pelletier S., Teixeira A., Laforet P., Genereau T., Simon A., Maisonobe T., Eymard B., Herson S. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 46:2002;467-474.
6. Dalakas M.C., Sivakumar K. The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis. Curr. Opin. Neurol. 9:1996;235-239.
7. DeGirolami U., Smith T.W. Pathology of skeletal muscle diseases. Am. J. Pathol. 107:1982;231-276.
8. Emslie-Smith A.M., Engel A.G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann. Neurol. 27:1990;343-356.
9. Engel A.G., Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Human Pathol. 17:1986;704-721.
10. Engel A.G., Biesecker G. Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Ann. Neurol. 12:1982;289-296.
11. Gasque P., Morgan B.P., Legoedec J., Chan P., Fontaine M. Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing. J. Immunol. 156:1996;3402-3411.
12. Goncalves F.G.P., Chimelli L., Sallum A.M.E., Marie S.K.N., Kiss M.H.B., Ferriani V.P.L. Immunohistological analysis of CD59 and membrane attack complex of complement in muscle in juvenile dermatomyositis. J. Rheumatol. 29:2002;1301-1307.
13. Kissel J.T., Mendell J.R., Rammohan K.W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N. Engl. J. Med. 314:1986;331-334.
14. Kumar S., Vinci J.M., Pytel B.A., Baglioni C. Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res. 53:1993;348-353.
15. Liprandi A., Bartoli C., Figarella-Branger D., Pellissier J.F., Lepidi H. Local expression of monocyte chemoattractant protein-1 (MCP-1), in idiopathic inflammatory myopathies. Acta Neuropathol. 97:1999;642-648.
16. Lundberg I., Brengman J.M., Engel A.G. Analysis of cytokine expression in muscle in inflammatory myopathies. Duchenne dystrophy, and non-weak controls. J. Neuroimmunol. 63:1995;9-16.
17. Maio M., Brasoveanu L.I., Coral S., Sigalotti L., Lamaj E., Gasparollo A., Visintin A., Altomonte M., Fonsatti E. Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review). Int. J. Oncol. 13:1998;305-318.
18. Mantegazza R., Bernasconi P., Confalonieri P., Cornelio F. Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. J. Neurol. 244:1997;277-287.
19. Mascaro J.M. Jr., Hausmann G., Herrero C., Grau J.M., Cid M.C., Palou J., Mascaro J.M. Membrane attack complex deposits in cutaneous lesions of dermatomyositis. Arch. Dermatol. 131:1995;1386-1392.
20. Mastaglia F.L., Garlepp M.J., Phillips B.A., Zilko P.J. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve. 27:2003;407-425.
21. Mendell J.R., Garcha T.S., Kissel J.T. The immunopathogenetic role of complement in human muscle disease. Curr. Opin. Neurol. 9:1996;226-234.
22. Meri S., Waldmann H., Lachmann P.J. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab. Invest. 65:1991;532-537.
23. Navenot J.M., Villanova M., Lucas-Heron B., Malandrini A., Blanchard D., Louboutin J.P. Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers. Muscle Nerve. 20:1997;92-96.
24. O'Brien K.D., Pineda C., Chiu W.S., Bowen R., Deeg M.A. Glycosylphosphatidylinositol-specific phospholipase D is expressed by macrophages in human atherosclerosis and colocalizes with oxidation epitopes. Circulation. 99:1999;2876-2882.
25. Pimorady-Esfahani A., Grounds M.D., McMenamin P.G. Macrophages and dendritic cells in normal and regenerating murine skeletal muscle. Muscle Nerve. 20:1997;158-166.
26. Plotz P.H., Rider L.G., Targoff I.N., Raben N., O'Hanlon T.P., Miller F.W. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann. Intern. Med. 122:1995;715-724.
27. Rollins S.A., Zhao J., Ninomiya H., Sims P.J. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J. Immunol. 146:1991;2345-2351.
28. Schwartz H.A., Slavin G., Ward P., Ansell B.M. Muscle biopsy in polymyositis and dermatomyositis: a clinico-pathological study. Ann. Rheum. Dis. 39:1980;500-507.
29. Sewry C.A., Dubowitz V., Abraha A., Luzio J.P., Campbell A.K. Immunocytochemical localization of complement components C8 and C9 in human diseased muscle. The role of complement in muscle fibre damage. J. Neurol. Sci. 81:1987;141-153.
30. Spuler S., Engel A.G. Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies. Neurology. 50:1998;41-46.
31. Tada T., Okada H., Okada N., Tateyama H., Eimoto T. Expression of 20 KD homologous restriction factor of complement on myocardial cells: an immunohistochemical study using acetone-fixed and paraffin-embedded tissues. J. Histochem. Cytochem. 41:1993;119-122.
32. Targoff I.N., Miller F.W., Medsger T.A., Oddis C.V. Classification criteria for the idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 9:1997;527-535.
33. Whitaker J.N., Engel W.K. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N. Engl. J. Med. 286:1972;333-338.
34. Zar J.H. Biostatistical Analysis. 1974;281-300 Prentice-Hall, Englewood Cliffs, NJ.